Graphcore-backer snaps up stake in Covid-19 mutation tracking firm
Amadeus Capital Partners bought a $24m stake in the company whose technology it said was at a tipping point
14 February 2021 • 6:00am
Graphcore-backer Amadeus Capital Partners has snapped up a $24m (£17.4m) stake in Britain s leading Covid-19 mutation tracker Oxford Nanopore, as speculation swirls over a London listing for the company.
The investment, which is understood to value Oxford Nanopore at around £1.7bn, in line with its funding round last summer, sees Amadeus join investors in the company including Tencent and Abu Dhabi s International Holdings.
Amadeus said it bought the stake from minority investors in the company, having initially been planning to take part in a funding round in 2019, but failing to move fast enough amid significant investor interest.
Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, as-is , and you use it at your own risk. The contents of all Chat messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates. London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.
Shares in a little-known company, Gamestop, more than doubled to $319 as Reddit users encouraged each other to buy the stock. It has now rocketed more than 1300 per cent in a month.
Oxford spin-out Bodle secures Series A funding extension siliconrepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from siliconrepublic.com Daily Mail and Mail on Sunday newspapers.
Neil Woodford stock slashed 70% hitting fund and trust investors
Schroder UK Public Private Trust reckons the cash exit of unnamed investors means fundamentals not reflected in valuation
The valuation of a Neil Woodford stock has been slashed 70% in a venture capital deal hitting investors in the fallen star fund manager’s former flagship fund and investment trust.
A regulatory filing from the Schroder UK Public Private trust, previously the Woodford Patient Capital Trust, revealed its next valuation for net asset value at the year’s end will see the value of Ombu downgraded 71%, from £14m at the start of the quarter to £4m.